Published in Cancer Weekly, July 26th, 2005
"This decision is proof of the impressive survival benefit that Tarceva offers patients with late stage lung cancer," said William M. Burns, CEO Division Roche Pharma.
"This brings new hope to lung cancer patients who have currently very limited treatment options."
Tarceva is the only EGFR-targeted treatment to have shown a significant survival benefit in patients with non...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.